Intermittent preventive treatment in pregnancy with sulphadoxine-pyrimethamine plus dihydroartemisinin-piperaquine to reduce adverse pregnancy outcomes and prevent malaria in Papua New Guinea: a randomised controlled trial [ 1/1/2022 - 6/30/2025 ]

Research Grant

Brief description Millions of pregnancies are complicated by malaria worldwide. Monthly sulphadoxine-pyrimethamine (SP) treatments, the current treatment strategy, no longer protects from malaria but improves birth outcomes through non-malarial effects. Dihydroartemisinin-piperaquine clears malaria but babies are smaller compared to women who received SP. A clinical trial of their combination has potential to substantially improve health outcomes for women and babies in Papua New Guinea and beyond.

Funding Amount $2,938,453

Funding Scheme Clinical Trials and Cohort Studies Grants

Chief Investigator Dr Holger Unger

Notes Clinical Trials and Cohort Studies Grants